Phase 3 SPLASH
Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto
Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto